Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Winter;13(4):212-214.
doi: 10.1900/RDS.2016.13.212. Epub 2017 Feb 10.

Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3

Yu-Hung Chang  1 , Der-Wei Hwu  1 , Wei-Pin Kao  2 , Yau-Jiunn Lee  1
Affiliations

Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3

Yu-Hung Chang et al. Rev Diabet Stud. 2016 Winter.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors reported no conflict of interests.

Figures

Figure 1
Figure 1. Forest plot of atorvastatin and rosuvastatin treatment results in CVD prevention studies
The meta-analysis of atorvastatin vs. placebo in CVD prevention studies showed that atorvastatin benefited CVD prevention with an odds ratio of 0.82 (95% CI: 0.75-0.90). In contrast, the meta-analysis of rosuvastatin vs. placebo found no significant benefit of rosuvastatin in CVD prevention, with an odds ratio of 0.84 (95% CI: 0.70-1.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 380(9841):581–590. - PMC - PubMed
    1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45. - PubMed
    1. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A. et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–2031. - PubMed
    1. Chang YH, Hsieh MC, Wang CY, Lin KC, Lee YJ. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients - a systematic review and meta-analysis. Rev Diabet Stud. 2013;10(2-3):157–170. - PMC - PubMed
    1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. - PubMed

LinkOut - more resources